Espinosa, Enrique; Berciano-Guerrero, Miguel-Ángel; Muñoz-Couselo, Eva; Puertolas, Teresa; Manzano, José-Luis; Soria, Ainara; Ayala-de-Miguel, Pablo; Crespo, Guillermo; Gutiérrez-Sanz, Lourdes; Cerezuela-Fuentes, Pablo; Aguado-de-la-Rosa, Carlos; Majem, Margarita; García-Castaño, Almudena; Berrocal, Alfonso; García-Arroyo, Francisco-Ramón; De-la-Borbolla, María-Rodriguez; Bellido, Lorena; Medina-Martínez, Javier; Fernández, Luis-Antonio; Martín-Carnicero, Alfonso; López-Castro, Rafael; Bujosa-Rodríguez, Aída; Jose-Lecumberri, Ma; Guzmán, José-Carlos-Villa; Campos-Balea, Begoña; Rodríguez, Joaquín-Fra; Valdivia-Bautista, Javier; Pérez, Víctor-Navarro; Mujika, Karmele; Corral-Subias, Mónica; Hernández, Berta; Martín-Algarra, Salvador; Márquez-Rodas, Iván
(SPRINGER INT PUBL AG, 2025-11-28)
PURPOSE: Anti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become ...